Atrial Fibrillation Paroxysmal
Conditions
Brief summary
Cryoballoon pulmonary vein isolation (PVI) has emerged as an alternative to radiofrequency in the treatment of drug-resistant atrial fibrillation (AF). (1) Cryoablation offers potential advantages over radiofrequency, including shorter procedure times, decreased fluoroscopy time, shorter hospital length of stay, and different rates and types of complications. (2) The efficacy over a mean follow-up of one year with cryoablation for AF is comparable to that of radiofrequency ablation in a prospective randomized trial, with a lower major complication rate (3, 4). In recent years, AF cryoablation has established itself as a real alternative to RF ablation, to the point that this ablative source is chosen in one out of five European patients undergoing PV isolation. 70-80% of patients maintain sinus rhythm after a first procedure, showing an efficacy rate equivalent to ablation by RF. It is also comparable to RF when it comes to safety. Phrenic nerve palsy remains the major concern of cryoablation, accounting for 40% of periprocedural complications. A reduction in total procedure time and less dependence on the operator's experience make cryoablation an attractive choice for centres starting an AF ablation program. In conclusion, we do not yet have definitive data to affirm the superiority of one energy source over the other. Generally the choice depends on the availability of the centre and on the experience of the operator. Pulse field ablation (PFA): Vivek Y. Reddy demonstrates that in patients with paroxysmal atrial fibrillation, PFA rapidly and efficiently isolates PVs with a degree of tissue selectivity and a safety profile(1).PFA can achieve a high degree of durable PV isolation with a comparable efficiency than another techniques (RF or CRYO) at one year follow-up (2) Cryoablation has been a recognised technique for the ablation of atrial fibrillation for many years, with many studies comparing the technique to radiofrequency ablation with equal results. Studies are underway to compare radiofrequency AF ablation versus PFA (BEAT-AF study). A randomized study to compare two methods of cryoablation versus PFA will be necessary to validate the non-inferiority of the technique.
Interventions
DEVICEPulse field ablation
ablation of paroxysmal atrial fibrillation by Pulse field ablation
ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
Sponsors
University Hospital, Grenoble
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient is of legal age to participate in the study (age \>18 years) * The patient is eligible for ablation of paroxysmal atrial fibrillation * The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial * The patient is able and willing to return for required follow-up visits and examinations
Exclusion criteria
* Previous AF ablation * Persistent and permanent AF * The patient is contraindicated or allergic to oral anticoagulation * The patient or legal representative is enable to understand and willing to provide written informed consent to participate in the trial * The patient is enable and willing to return for required follow-up visits and examinations * Pregnant or nursing patient * Patient in exclusion period of another interventional study, * Patient under administrative or judicial supervision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| proportion of subjects experiencing one-year single-procedure clinical success | 12 months | successful index of AF ablation, absence of atrial arrhythmia recurrence on any type of recording (30 sec by TTM (event monitor), holters, 12-lead ECGs, rhythm strip or other diagnostic ECG documentation), absence of use of class I or III AAD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in AF-specific quality of life | 6 and 12 months | AFEQT questionnaire |
| Proportion of patients with death | 12 months | Death from any causes |
| Proportion of patients with first hospitalization for cardiovascular causes. | 12 months | First hospitalization for cardiovascular causes |
| Proportion of patients with acute complication related to the procedure | during the procedure or one day after | tamponade, stroke, myocardial infarction, other |
| Health-related quality of life | 6 and 12 months | SF-12 questionnaire. |
| Total time of fluoroscopy | during the procedure | Total time of fluoroscopy in minutes |
| Proportion of patients with embolic events from arrhythmia | 12 months | Stroke |
| Long term complications related to the procedure | 12 months | phrenic palsy, pulmonary vein stenosis, pericarditis, other |
| Recurrence of atrial fibrillation | 12 months | Absence of atrial arrhythmia recurrence on any type of recording (30 sec by TTM (event monitor), holters, 12-lead ECGs, rhythm strip or other diagnostic ECG documentation), absence of use of class I or III AAD |
| Total procedure duration | during the procedure | Procedure duration in minutes |
Countries
France
Outcome results
None listed